Search Results
Feb 23, 2026, 12:00 ET New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA
capture the full complexity of the DNA and RNA landscape. Spun out of The University of Chicago and boasting Scientific Founder Professor Chuan He, Ellis Bio's portfolio goes beyond sequencing to provide insights into the DNA and RNA modifications that drive gene expression, collectively known as the epigenome
More news about: Ellis Bio Inc
Feb 23, 2026, 08:33 ET Consano Bio to Present at BIO Investment & Growth Summit 2026
During the presentation, Mr. Hall will provide an overview of Consano Bios' development strategy and clinical progress for C-1101, its lead investigational therapy being evaluated as a potential treatment for chronic lumbosacral
More news about: Consano Bio
Feb 23, 2026, 07:00 ET Promise Bio Launches Frontier Epiproteomic Innovation Grant, an R&D Access Initiative for Translational Epiproteomic Analysis
therapeutics with clear translational potential. This initiative will provide selected participants with deeper biological insights powered by Promise Bio's broad-epiproteomic platform and scientific expertise analysis from existing or newly-generated mass-spectrometry data. Under the program, selected
More news about: Promise Bio
Feb 20, 2026, 10:30 ET Sōlaria Biō Announces Study Demonstrating that the Microbe Blend in Bōndia™ Provides Maximum Bone Health Benefits
reinforces prior efficacy findings supporting its role as a medical food for bone health.Conducted in healthy adults, the study adds to Sōlaria Biō's growing body of mechanistic and clinical research on Bōndia previously published in
More news about: Sōlaria Biō
Feb 19, 2026, 17:31 ET Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
paediatric alopecia areata. Clinical studies reported notable hair regrowth, with sustained benefits observed even after treatment cessation.Q32 Bio's Bempikibart is a fully human monoclonal antibody that targets both the Interleukin-7 Receptor Alpha (IL-7Rα) and Thymic Stromal Lymphopoietin (TSLP).
More news about: DelveInsight Business Research, LLP
Feb 19, 2026, 09:00 ET Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated. CN Bio's human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable development of novel, safe, and effective
More news about: Devonian Health Group Inc.
Feb 18, 2026, 06:59 ET Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at
More news about: Q32 Bio
Feb 18, 2026, 01:00 ET FSS Future-Proofs Middle East Payments with Scalable, Sovereign Cloud Infrastructure
without compromising regulatory integrity.Solution | Migration to a sovereign enterprise private cloud within UAE bordersFSS selected BIOS Cloud, part of ZainTech, as its cloud service provider, leveraging its enterprise private cloud architecture and strong local data-centre footprint.
More news about: FSS
Feb 18, 2026, 01:00 ET FSS Future-Proofs Middle East Payments with Scalable, Sovereign Cloud Infrastructure
without compromising regulatory integrity.Solution | Migration to a sovereign enterprise private cloud within UAE bordersFSS selected BIOS Cloud, part of ZainTech, as its cloud service provider, leveraging its enterprise private cloud architecture and strong local data-centre footprint.
More news about: FSS
Feb 17, 2026, 16:05 ET Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 833155. An archived recording will be available on Nuvation Bio's website for 90 days following the event.About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some
More news about: Nuvation Bio Inc.
Feb 17, 2026, 16:01 ET HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Increased 52% YOY to Record $868 millionCompleted Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration TechnologyReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810
More news about: Halozyme Therapeutics, Inc.
Feb 17, 2026, 15:00 ET Levine Leichtman Capital Partners Announces Finance and Administration Team Promotions
reflecting their continued excellence and dedication. We look forward to the lasting impact they will continue to make in their new roles."Full bios of the professionals being promoted can be viewed here:
More news about: Levine Leichtman Capital Partners, LLC
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
available."A new exploratory cohort for grade 3 IDH1-mutant oligodendroglioma has also been added, with initial data expected in 2027. Nuvation Bio's pipeline also includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor that generated approximately
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
available."A new exploratory cohort for grade 3 IDH1-mutant oligodendroglioma has also been added, with initial data expected in 2027. Nuvation Bio's pipeline also includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor that generated approximately
More news about: Equity Insider
Feb 17, 2026, 08:00 ET Resurrect Bio announces $8.1M initial close of Series A led by Corteva
resistance products toward commercial partnerships, bringing solutions to farmers significantly faster than conventional breeding methods.Resurrect Bio's proprietary platform combines cutting-edge FloraFold® AI computational biology and high-throughput screening in plants to identify and resurrect disease
More news about: Resurrect Bio
Feb 17, 2026, 06:59 ET Q32 Bio Announces $10.5 Million Registered Direct Offering
www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements,
More news about: Q32 Bio
Feb 12, 2026, 10:00 ET BioNJ Elects Board Officers and Trustees
Klein, M.D., M.S., FACS, CEO, PTC Therapeutics; and Robert Zamboldi, MBA, Site Head, Real Estate & Facility Services, Novartis.Bios for Newly Elected Board Members:Mary Elizabeth Blake, MBA, MPH, Chief Corporate Affairs Officer, Amicus TherapeuticsMs.
More news about: BioNJ
Feb 11, 2026, 13:06 ET BronzeLens 2026 Superstars Weekend Pays homage to CBS' "Beyond the Gates"
SuperStar Honorees Photos and Bios click hereReel Women: Her Vision, Her Voice will kick off the BronzeLens 2026 Superstars Weekend on March 6, 2026. The event includes
More news about: BronzeLens Film Festival
Feb 11, 2026, 09:43 ET From Tech to Runway: TORRAS Ostand Cases Redefine Phone Case Fashion
sneakers. Now TORRAS reimagines that language for phone cases, giving it fresh meaning with every iteration.TORRAS's upcoming release, the O3 Air Bios, introduces the brand's latest biomimetic airbag technology. Inspired by the porous structure inside bird bones, the airbag efficiently absorbs and disperses
More news about: TORRAS Global
Feb 11, 2026, 09:00 ET Choice Cyber Solutions Announces Leadership Evolution to Support Continued Growth and Client Success
www.choicecybersolutions.com.Leadership Bios Alex Spigel Alex Spigel is Chief Executive Officer and Co-Founder of Choice Cyber Solutions, where she leads company strategy, growth,
More news about: Choice Cyber Solutions
Feb 11, 2026, 08:43 ET Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
strategic joint ventures, we are positioned to accelerate progress toward functional cures and extended healthy lifespans."Key elements of Avaí Bio's pipeline include:Diabetes Development Program: Genetically modified cell lines engineered to produce, store, and secrete insulin, combined
More news about: AVAI Bio Inc.
Feb 10, 2026, 16:05 ET Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
Merus N.V. and Skye Bioscience.Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and
More news about: Halozyme Therapeutics, Inc.
Feb 10, 2026, 11:17 ET Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing
Through this program, Made Scientific will serve as Streamline Bio's exclusive early adopter, design partner, and preferred CDMO partner for the co-development, integration, and validation of Streamline Bio's AI-driven robotic manufacturing platform in a GMP-ready environment. Activities
More news about: Made Scientific, Inc.
Feb 10, 2026, 09:00 ET The J.M. Smucker Co. Announces Senior Leadership Updates to Drive Continued Growth and Execution
which will be responsible for quality assurance, research and development, and other technical functions. Both roles will report to Ferguson.Bios for Marshall, Ferguson, Penrose, Wayne, and Crane, along with the rest of the Company's executive team, can be accessed at the Company's website: jmsmucker.com.The
More news about: The J.M. Smucker Co.
Feb 09, 2026, 11:54 ET The Trends We're Loving in 2026: Toy Association to Reveal What's Next in Toys & Play at Toy Fair®
global toy companies to identify the products and trends that will drive consumer spending on toys, games, and youth entertainment products. Trend expert bios are available in the
More news about: The Toy Association